{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:50:08Z","timestamp":1786632608564,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>(1) Background: Mucosal melanoma (MM) is a rare tumor, accounting for about 1% of all diagnosed melanomas. The etiology and pathogenesis of this tumor are unknown. It is characterized by an aggressive phenotype with poor prognosis and a low response rate to approved treatments. (2) Methods: We retrospectively analyzed the clinical features, treatments and outcomes of patients diagnosed with MM from different sub-sites (head and neck, gynecological and gastro-intestinal region) between 2013 and 2023 at our Institute. Survival times were estimated with the Kaplan\u2013Meier method. Multivariate Cox regression was used to test the independence of significant factors in univariate analysis. (3) Results: Twenty-five patients were included in this study; the disease was equally distributed among females and males. The median age at diagnosis was 74 years old. The majority had MM originating from the head and neck (56%), particularly from the nasal cavity. BRAF V600 mutations were detected in 16% of the study population, limited to gastro-intestinal and gynecological MM. At diagnosis, at least half the patients (52%) had the disease located also at distant sites. The median overall survival (OS) in the whole study population was 22 months, with a longer OS for patients diagnosed at an early stage (38 months, p &lt; 0.001). Longer OSs were reported for head and neck MM compared to other anatomic regions (0.06). Surgery of the primary tumor and radiotherapy were performed in 64% and 36% of the study population, respectively. Radiotherapy was performed only in head and neck MM. At multivariate analysis, the single factor that showed a reduced hazard ratio for death was radiotherapy. (4) Conclusions: The overall survival of MM from different sub-sites treated at our Italian Institution was 22 months, with better outcomes for early-stage disease and head and neck MM. Performing radiotherapy may have a protective effect on OS for head and neck MM. New treatment strategies are urgently needed to improve the outcome in this disease.<\/jats:p>","DOI":"10.3390\/curroncol31010042","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:54:01Z","timestamp":1706072041000},"page":"588-597","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-4711","authenticated-orcid":false,"given":"Rosa","family":"Falcone","sequence":"first","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Verkhovskaia","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Di Pietro","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Poti","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Samela","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luigia","family":"Carbone","sequence":"additional","affiliation":[{"name":"Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Morelli","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina Rita","family":"Zappal\u00e0","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zorika Christiana","family":"di Rocco","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Morese","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Piesco","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5991-8914","authenticated-orcid":false,"given":"Cristina Maria","family":"Failla","sequence":"additional","affiliation":[{"name":"Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Galitiis","sequence":"additional","affiliation":[{"name":"Department of Oncology, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"ref_1","first-page":"739","article-title":"Primary mucosal melanomas: A comprehensive review","volume":"5","author":"Mihajlovic","year":"2012","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/archoto.2011.46","article-title":"Mucosal melanoma of the head and neck: Predictors of prognosis","volume":"137","author":"Shuman","year":"2011","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1245\/s10434-014-4215-3","article-title":"Melanoma of the vulva and vagina: Principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases","volume":"22","author":"Seifried","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1245\/s10434-022-11670-6","article-title":"An Evidence-Based Staging System for Mucosal Melanoma: A Proposal","volume":"29","author":"Cui","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/archotol.129.8.864","article-title":"The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region","volume":"129","author":"Owens","year":"2003","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1158\/1078-0432.CCR-20-1558","article-title":"PD-1 Blockade in Chinese versus Western Patients with Melanoma","volume":"26","author":"Shoushtari","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Dumaz, N., Jouenne, F., Delyon, J., Mourah, S., Bensussan, A., and Lebb\u00e9, C. (2019). Atypical. Cancers, 11.","DOI":"10.3390\/cancers11081133"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4149\/neo_2017_419","article-title":"BRAF inhibitors: Efficacious and tolerable in BRAF-mutant acral and mucosal melanoma","volume":"64","author":"Bai","year":"2017","journal-title":"Neoplasma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"680407","DOI":"10.3389\/fimmu.2021.680407","article-title":"Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions","volume":"12","author":"Mao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00262-019-02351-7","article-title":"Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma","volume":"68","author":"Rossoni","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jaad.2018.09.054","article-title":"Predictors of mucosal melanoma survival in a population-based setting","volume":"81","author":"Altieri","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","unstructured":"NCCN (2024). Head and Neck Cancers. NCCN Guidelines in Oncology, NCCN. Version 2.2024."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2017.05.014","article-title":"Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma","volume":"81","author":"Heppt","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1111\/jdv.16306","article-title":"Prognostic factors in 161 patients with mucosal melanoma: A study of German Central Malignant Melanoma Registry","volume":"34","author":"Sarac","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cncr.30473","article-title":"Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma","volume":"123","author":"Hou","year":"2017","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Aashiq, M., Silverman, D.A., Na\u2019ara, S., Takahashi, H., and Amit, M. (2019). Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. Cancers, 11.","DOI":"10.3390\/cancers11091382"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1111\/jdv.14353","article-title":"Mucosal melanoma: Clinical, histological and c-kit gene mutational profile of 86 French cases","volume":"31","author":"Cinotti","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.2217\/fon-2019-0465","article-title":"Survival outcomes of mucosal melanoma in the USA","volume":"15","author":"Vrable","year":"2019","journal-title":"Future Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaad.2016.08.007","article-title":"Mucosal melanomas in the racially diverse population of California","volume":"76","author":"Altieri","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","first-page":"165","article-title":"Comparison of International Guidelines on Mucosal Melanoma of the Head and Neck: A Comprehensive Review of the Role of Radiation Therapy","volume":"30","author":"Pittaka","year":"2016","journal-title":"In Vivo"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hed.26470","article-title":"The effectiveness of radiotherapy in the treatment of head and neck mucosal melanoma: Systematic review and meta-analysis","volume":"43","author":"Clover","year":"2021","journal-title":"Head Neck"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Li, W., Yu, Y., Wang, H., Yan, A., and Jiang, X. (2015). Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: A meta-analysis. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1750-7"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jcms.2015.02.011","article-title":"Postoperative adjuvant radiotherapy improves loco-regional recurrence of head and neck mucosal melanoma","volume":"43","author":"Wushou","year":"2015","journal-title":"J. Craniomaxillofac. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hed.24652","article-title":"Mucosal melanoma of the upper airways tract mucosal melanoma: A systematic review with meta-analyses of treatment","volume":"39","author":"Jarrom","year":"2017","journal-title":"Head Neck"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jogc.2018.07.011","article-title":"Melanoma of the Vulva and Vagina: Surgical Management and Outcomes Based on a Clinicopathologic Reviewof 68 Cases","volume":"41","author":"Sinasac","year":"2019","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"Larkin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41416-018-0207-6","article-title":"Antitumour activity of pembrolizumab in advanced mucosal melanoma: A post-hoc analysis of KEYNOTE-001, 002, 006","volume":"119","author":"Hamid","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2217\/imt-2018-0030","article-title":"A study of the clinical characteristics and prognosis of advanced mucosal and cutaneous melanoma in a Chinese population","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1002\/cam4.3789","article-title":"Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade","volume":"10","author":"Buchbinder","year":"2021","journal-title":"Cancer Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semcancer.2019.09.013","article-title":"The mutational landscape of mucosal melanoma","volume":"61","author":"Nassar","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lorenz, A., Koz\u0142owski, M., Lenkiewicz, S., Kwiatkowski, S., and Cymbaluk-P\u0142oska, A. (2022). Cutaneous Melanoma versus Vulvovaginal Melanoma-Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy. Cancers, 14.","DOI":"10.3390\/cancers14205123"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","article-title":"Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets","volume":"10","author":"Newell","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e004036","DOI":"10.1136\/jitc-2021-004036","article-title":"Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis","volume":"10","author":"Li","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G","volume":"37","author":"Sheng","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2021.07.018","article-title":"Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma","volume":"156","author":"Tang","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.20.00902","article-title":"Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma","volume":"39","author":"Yan","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/1\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:46:50Z","timestamp":1760104010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/1\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["curroncol31010042"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31010042","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}